JP2016534062A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534062A5
JP2016534062A5 JP2016525504A JP2016525504A JP2016534062A5 JP 2016534062 A5 JP2016534062 A5 JP 2016534062A5 JP 2016525504 A JP2016525504 A JP 2016525504A JP 2016525504 A JP2016525504 A JP 2016525504A JP 2016534062 A5 JP2016534062 A5 JP 2016534062A5
Authority
JP
Japan
Prior art keywords
immune complex
lyophilized composition
spdb
complex preparation
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525504A
Other languages
English (en)
Japanese (ja)
Other versions
JP6813355B2 (ja
JP2016534062A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/072558 external-priority patent/WO2015059147A1/en
Publication of JP2016534062A publication Critical patent/JP2016534062A/ja
Publication of JP2016534062A5 publication Critical patent/JP2016534062A5/ja
Application granted granted Critical
Publication of JP6813355B2 publication Critical patent/JP6813355B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525504A 2013-10-25 2014-10-21 新規な安定製剤 Expired - Fee Related JP6813355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13190276.9 2013-10-25
EP13190276 2013-10-25
PCT/EP2014/072558 WO2015059147A1 (en) 2013-10-25 2014-10-21 A novel stable formulation

Publications (3)

Publication Number Publication Date
JP2016534062A JP2016534062A (ja) 2016-11-04
JP2016534062A5 true JP2016534062A5 (cg-RX-API-DMAC7.html) 2018-12-27
JP6813355B2 JP6813355B2 (ja) 2021-01-13

Family

ID=49552164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525504A Expired - Fee Related JP6813355B2 (ja) 2013-10-25 2014-10-21 新規な安定製剤

Country Status (15)

Country Link
US (2) US20160250349A1 (cg-RX-API-DMAC7.html)
EP (1) EP3060256B1 (cg-RX-API-DMAC7.html)
JP (1) JP6813355B2 (cg-RX-API-DMAC7.html)
CY (1) CY1121791T1 (cg-RX-API-DMAC7.html)
DK (1) DK3060256T3 (cg-RX-API-DMAC7.html)
ES (1) ES2735645T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045020T2 (cg-RX-API-DMAC7.html)
LT (1) LT3060256T (cg-RX-API-DMAC7.html)
PL (1) PL3060256T3 (cg-RX-API-DMAC7.html)
PT (1) PT3060256T (cg-RX-API-DMAC7.html)
RS (1) RS58856B1 (cg-RX-API-DMAC7.html)
SI (1) SI3060256T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909034T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015059147A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
IL267917B2 (en) * 2017-01-19 2023-10-01 Bayer Pharma AG Novel stable formulation for fxia antibodies
CA3073383C (en) 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
JP2025517947A (ja) 2022-05-23 2025-06-12 ロジックバイオ セラピューティクス, インコーポレイテッド 遺伝子治療組成物及びその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101424624B1 (ko) * 2003-05-14 2014-07-31 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
BRPI0614100A2 (pt) * 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
CN103826661B (zh) * 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
CN103501825B (zh) * 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
WO2013003680A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations

Similar Documents

Publication Publication Date Title
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
PE20170780A1 (es) Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
JP2016034978A5 (cg-RX-API-DMAC7.html)
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
EA201492021A1 (ru) Антительный состав
JP2016534062A5 (cg-RX-API-DMAC7.html)
JP2016513069A5 (cg-RX-API-DMAC7.html)
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
JP2017531682A5 (cg-RX-API-DMAC7.html)
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2016510326A5 (cg-RX-API-DMAC7.html)
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
AR103544A1 (es) FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
JP2016515623A5 (cg-RX-API-DMAC7.html)
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof